Two new PET radiotracers have outperformed the only current Food and Drug Administration (FDA) approved radiotracer for ...

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test developed at the ...

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test developed at the University of Pittsburgh School of Medicine can detect small amounts of the ...

(HealthDay News) — Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the Alzheimer’s Association and the Society for Nuclear Medicine ...

Scientists have developed two new imaging agents that work better than the only currently approved one for detecting tau ...

Rabinovici et al, Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup, Alzheimer's ...

Two new PET radiotracers have outperformed the only currently Food and Drug Administration (FDA) approved radiotracer for ...

In pursuit of this vision, subsidiaries of Enigma have provided the best-in-class Tau and Amyloid PET imaging biomarkers, MK-6240 and NAV-4694, to our partners to enable their research efforts.

Lantheus' oncology portfolio includes Pylarify (piflufolastat F 18) and a growing pipeline addressing various solid tumours.

In pursuit of this vision, subsidiaries of Enigma have provided the best-in-class Tau and Amyloid PET imaging biomarkers, MK-6240 and NAV-4694, to our partners to enable their research efforts.

By quantifying the amount of tau in the brain tissue with PET imaging, physicians can appropriately stage Alzheimer’s disease in patients and determine the best treatment options. “Identifying ...

By quantifying the amount of tau in the brain tissue with PET imaging, physicians can appropriately stage Alzheimer's disease in patients and determine the best treatment options. "Identifying tau ...